Thrombolysis in strokes carries large riskBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7108.563h (Published 06 September 1997) Cite this as: BMJ 1997;315:563
- Kamran Abbasi
Thrombolysis in acute ischaemic stroke carries a substantial risk and uncertain benefit, according to a systematic review of the evidence.
In the United States tissue plasminogen activator (tPA) is licensed for use within three hours of a stroke, and its use in this setting is recommended by American medical organisations. However, Dr Joanna Wardlaw, senior lecturer in the department of neuroradiology at the University of Edinburgh, and her team of researchers, concludes that the evidence does not support such an approach and more randomised trials are needed (Lancet 1997;350:607-14).
Her team carried …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial